Histrelin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Histrelin: From GnRH Agonist Therapy to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Histrelin is a GnRH (gonadotropin-releasing hormone) agonist; the evidence pack does not contain a confirmed original indication or approved label text for this drug. The TxGNN model’s top-ranked prediction is Ambras Type Hypertrichosis Universalis Congenita (a rare congenital hair-growth syndrome), but this pairing is supported by 0 clinical trials and 0 publications, and the model’s own mechanistic rationale rates the biological link as weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record in this evidence pack (drug is not currently marketed; no approved indication text available) |
| Predicted New Indication | Ambras Type Hypertrichosis Universalis Congenita |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for histrelin is not available in this evidence pack (flagged as a High-severity data gap). Based on the mechanistic notes attached to this drug’s other predicted indications, histrelin is understood to be a synthetic GnRH agonist: with continuous dosing it desensitizes the anterior pituitary, suppressing LH/FSH release and downstream gonadal steroid production.
Ambras type hypertrichosis universalis congenita is a rare congenital syndrome linked to structural gene loci (commonly cited around 8q22), characterized by excessive generalized hair growth from birth. There is no established pathological connection between hypothalamic-pituitary-gonadal axis suppression and this syndrome’s underlying genetic cause.
The evidence pack’s own analysis concurs: it explicitly describes the mechanistic link as weak, with no known pathological connection to the GnRH axis, and no supporting clinical or literature evidence of any kind. This candidate should be read as a high TxGNN similarity score without corroborating biological or clinical signal — it does not currently constitute a credible repurposing hypothesis.
Note for reviewers: among this drug’s other TxGNN-ranked candidates, rank 10 (idiopathic central precocious puberty) carries materially stronger support — L1 evidence with a 1993 pharmacology review and two cohort studies directly describing histrelin’s therapeutic role in this condition, consistent with its known GnRH-agonist mechanism. That candidate warrants separate evaluation and is not the subject of this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No authorization records available — histrelin is not currently marketed in the reference jurisdiction covered by this evidence pack (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence linking histrelin to Ambras type hypertrichosis universalis congenita, and the proposed mechanistic link is assessed as biologically implausible even by the model’s own rationale. The prediction score alone is insufficient to justify further investment.
To proceed, the following is needed:
- TFDA/FDA label data confirming histrelin’s approved indications and warnings (currently a blocking data gap)
- Confirmed mechanism-of-action documentation (currently a high-severity data gap)
- Any preclinical or case-level evidence specifically connecting GnRH-axis suppression to hair-shaft/follicle pathology in this syndrome, before allocating further review resources
- Consider redirecting evaluation effort toward the higher-evidence candidate in this same pack (idiopathic central precocious puberty, L1/S3, “Proceed with Guardrails”), which already has direct literature support for histrelin’s use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.